","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"about":[],"publisher":{"@type":"Organization","@id":"https://www.fool.com/","name":"The Motley Fool","url":"https://www.fool.com/","logo":{"@type":"ImageObject","url":"https://g.foolcdn.com/misc-assets/logo-tmf-primary-7-magenta-royalpurple.svg","width":"157","height":"43"},"brand":"The Motley Fool","contactPoint":{"@type":"ContactPoint","contactType":"Media Inquiries","email":"
[email protected]"},"publishingPrinciples":"https://www.fool.com/about/","sameAs":["https://www.fool.com/about/","https://en.wikipedia.org/wiki/The_Motley_Fool","https://www.wikidata.org/wiki/Q7752442","https://www.linkedin.com/company/the-motley-fool","https://www.facebook.com/themotleyfool/","https://x.com/themotleyfool","https://www.instagram.com/themotleyfoolofficial/","https://www.youtube.com/channel/UCpRQuynBX9Qy9tPrcswpPag","https://www.pinterest.com/themotleyfool/","https://www.tiktok.com/@themotleyfoolofficial","https://www.google.com/search?kgmid=/m/0578mk"]},"description":"AstraZeneca leaves its partnership with Rigel following lackluster results from Fostamatinib's late-stage trials.","image":{"@type":"ImageObject","height":"630","width":"1200"}}","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"inLanguage":"en-US"}
